Company Snapshot: Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. The company’s lead product candidate, Omadacycline, is a novel investigational antibiotic with both once-daily intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), acute bacterial skin and skin structure infections (ABSSSI), and urinary tract infections (UTI). A modernized tetracycline, omadacycline is specifically designed to overcome tetracycline resistance and exhibits activity across a broad spectrum of bacteria, including Gram-positive, Gram-negative, anaerobes, atypical bacteria, and other drug-resistant strains.
- Feb 14 2019 Paratek Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference
- Feb 13 2019 Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results on February 27, 2019
- Feb 6 2019 New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Paratek’s NUZYRA™ (Omadacycline) For Pneumonia and Skin Infections
- Feb 5 2019 Paratek Pharmaceuticals Launches NUZYRA™ (Omadacycline) in the United States